A PHASE IIA MULTICENTER, OPEN-LABEL, 12-WEEK STUDY TO INVESTIGATE THE PHARMACOKINETICS AND SAFETY AND TO PROVIDE PROOF OF MECHANISM OF ALOGABAT IN CHILDREN AND ADOLESCENTS AGED 5–17 YEARS WITH ANGELMAN SYNDROME (AS) WITH DELETION GENOTYPE

Torna ai Trials